Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the Investigator, may interfere with oral drug absorption
Unable to swallow tablets, patients with malabsorption syndrome, or any other GI disease or GI function that could interfere with absorption of study treatment
Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastro intestinal function or GI disease
Have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of AG-, including any unresolved nausea, vomiting, or diarrhea that is National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade >.
Active gastrointestinal (GI) conditions and uncontrolled irritable bowel disease or pre-existing GI disorders that may interfere with proper absorption of the study drug
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of venetoclax
Has malabsorption due to prior gastrointestinal (GI) surgery or GI disease
GI condition that might limit absorption of oral agents
Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption.
Impaired gastrointestinal (GI) function or GI disease that may alter absorption of ceritinib or inability to swallow
Presence of active gastrointestinal (GI) disease (including GI bleeding or ulceration) or other condition that could affect GI absorption (e.g. malabsorption syndrome, history of biliary tract disease), including refractory nausea or vomiting, or chronic GI disease which may affect absorption or tolerance to oral medications
Impairment of gastro intestinal (GI) function or GI disease.
Patients who are unable to swallow tablets, patients with malabsorption syndrome, or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with absorption of study treatment
Patients unable to swallow tablets, patients with malabsorption syndrome, or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with absorption of study treatment
Patient is unable to swallow oral medications or has impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption (including, but not limited to active inflammatory bowel disease, malabsorption syndrome); concomitant therapy with antacids and anti-emetics is permissible
Major surgery to the upper GI tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption
Patients unable to swallow tablets, patients with malabsorption syndrome, or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with absorption of study treatment
Impairment of GI function or GI disease that may significantly alter the absorption of INC
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Impaired gastrointestinal (GI) function or GI disease that may alter absorption of ceritinib or inability to swallow up to five ceritinib capsules daily
Patients with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LCL as per physicians opinion
Patients with known significant impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of quizartinib.
Impairment of GI function
Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs
Patient must not have prior gastrointestinal (GI) surgery or GI disease that might interfere with the absorption of TRC
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-, including any unresolved nausea, vomiting, or diarrhea that is Common Terminology Criteria for Adverse Events (CTCAE) grade > 
Must be able to swallow capsules and have no evidence of gastrointestinal (GI) tract abnormality that would alter the absorption of oral medications
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the swallowing absorption of panobinostat and MLN
Patients with known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of sorafenib
Patients with known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of midostaurin; patients with gastric bypass surgery are excluded
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of GS-, including any unresolved nausea, vomiting, or diarrhea that is Common Terminology Criteria for Adverse Events (CTCAE) Grade > 
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade >.
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of GS-, including any unresolved nausea, vomiting, or diarrhea that is Common Terminology Criteria for Adverse Events (CTCAE) Grade > 
Patients with known severe impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of sorafenib
Any gastrointestinal (GI) disorder or liver disease
Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract.
Impairment of gastrointestinal (GI) function
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Impairment of GI function or GI disease that may significantly alter capecitabine drug absorption
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of ceritinib or LEE
Presence of GI fistula
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LCL
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of midostaurin
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of PANOBINOSTAT or RUXOLITINIB
History of gastrointestinal (GI) surgery within the past  days; if >  days since GI surgery, must have confirmation of complete healing before initiating treatment with study drug
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Malabsorption due to prior gastrointestinal (GI) surgery, GI disease
Subjects are willing to undergo or must have had an endoscopy of the upper and/or lower GI tract and biopsy to confirm GI GVHD.
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Major gastrointestinal (GI) disease as defined but not limited to the following: history of inflammatory bowel disease or other illness resulting in chronic diarrhea, known achlorhydria or history of GI surgery that could reduce the acidity of the stomach, acute pancreatitis or cholecystitis within  months prior to Baseline, or GI disease that may interfere with the absorption of orally-administered drugs.
Impairment of GI function or GI disease that could interfere with the absorption of selinexor, including obstructed GI tract and uncontrolled vomiting or diarrhea.
Impairment of gastrointestinal (GI) function or GI disease that might significantly alter the absorption of study drug
Impaired GI function or GI disease
Patients with gastrointestinal (GI) absorptive problems making it unlikely to absorb study medication or more likely to experience GI toxicities
RECURRENT/ PROGRESSIVE DIPG (STRATUM ): Patients have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat; for example severe inflammatory bowel disease
NON-PROGRESSED DIPG (STRATUM ): Patients have impairment of GI function or GI disease that may significantly alter the absorption of panobinostat; for example severe inflammatory bowel disease
Impairment of GI function or GI disease that may significantly alter the absorption of ceritinib
Patient must not have prior gastrointestinal (GI) surgery or GI disease that might interfere with the absorption of terameprocol
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LBH
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade >
Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug.
Impairment of GI function or GI disease that may significantly alter the absorption of panobinostat.
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral WNT/LGX
Impaired GI function or GI disease that may interfere with absorption of AZD or patients unable to take oral medication
Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption
Impairment of GI function or GI disease that could interfere with the absorption of AEB or everolimus.
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Impairment of gastro-intestinal (GI) function or GI disease that may significantly alter the absorption of LEE such as patients with a history of GI surgery which may result in intestinal blind loops and patients with clinically significant gastroparesis, unresolved nausea, vomiting, or diarrhea of CTCAE grade > 
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Impairment of GI function or GI disease that may significantly alter the absorption of LBH
Presence of active gastrointestinal (GI) disease (including GI bleeding or ulceration) or other condition that could affect GI absorption) (e.g. malabsorption syndrome, history of biliary tract disease)
Impaired gastrointestinal function (GI) or GI disease that may significantly alter the absorption of oral medications
History of clinically-significant gastrointestinal (GI) disease; GI perforation within  year; GI bleeding or acute pancreatitis within  months; or diverticulitis within  weeks of first study drug administration
History of malabsorption or other gastrointestinal (GI) disease that may significantly alter the absorption of LAM-A
History of GI ulcers, chronic GERD, or GI bleeding in the past  years
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade >
Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption